LordsMed, the global healthcare division of Lord’s Mark Industries Ltd., has launched a set of 10 world-class re-agents for Triglycerides, Uric Acid, Alkaline Phosphatase, Bilirubin, Calcium (Arsenazo III), Creatinine, Glucose, Serum Glutamic Oxaloacetic Transaminase (SGOT)/Aspartate Aminotransferas, Serum Glutamic Pyruvic Transaminase (SGPT), Alanine Aminotransferase (ALT) and Total Protein. These re-agents come with 99.7 percent accuracy, the highest level of sensitivity, a shelf-life of 24 months, unique packaging and competitive price-points. The company has filed India patents for these re-agents which will strengthen the preventive healthcare mechanism for critical diseases.
LordsMed plans to manufacture re-agents at its Maharashtra facility and distribute them to pathological labs, hospitals, and research institutes through its Pan-India distribution network of over 300 dealers. The company plans to export re-agents to key global markets, aiming to generate revenue by supplying them to Pan India, SAARC, African, and Eastern Europe countries within a few years. Sachidanand Upadhyay, MD, Lord’s Mark Industries Ltd. said, “With our robust manufacturing capacity and domestic and global distribution network, we are working towards meeting the growing demand for quality re-agents across regions.”
Lords Mark Industries is collaborating with IIT Bombay and Bhabha Atomic Research Centre to create world-class patent products for critical diseases like sickle cell, oral cancer, and tuberculosis. The aim is to develop affordable, high-accuracy re-agents.
